A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

Trial Profile

A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2013 The extension study has been completed, according to the ClinicalTrials.gov record.
    • 16 Jul 2013 The extension study has been completed, according to the ClinicalTrials.gov record.
    • 01 Apr 2011 Extension study results published in the Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top